Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05206227 · ClinicalTrials.gov registry record · Early Phase 1
Histamine as a Molecular Transducer of Adaptation to Exercise
A Early Phase 1 study of Postexercise Hypotension, sponsored by University of Oregon.
- Active
- Registry status
- Early Phase 1
- Development phase
- 80
- Enrollment target
- 1
- Study location
NCT05206227 is a Early Phase 1 study of Postexercise Hypotension that is active but no longer recruiting, run by University of Oregon. The registered enrollment target is 80 participants. The trial reports 1 study location across 1 state.
The verdict
NCT05206227, a Early Phase 1 study of Postexercise Hypotension, is active but no longer recruiting, sponsored by University of Oregon.
- ACTIVE NOT RECRUITING
- Registry status
- Early Phase 1
- Development phase
- 80 participants
- Enrollment target
- 1
- Study location
Study Summary
This study is investigating the role of histamine in generating adaptation to exercise
Conditions Studied
Interventions
- BEHAVIORAL Aerobic Exercise
- DRUG Antihistamine
- DRUG alpha-FMH
- BEHAVIORAL Resistance and Aerobic Exercise
Study Locations (1)
Oregon
- University of Oregon - Eugene
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 80 participants |
| Start Date | 2021-07-28 |
| Est. Completion | 2027-03-31 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05206227
The ClinicalTrials.gov registry entry for NCT05206227 describes a study currently listed as active not recruiting, categorized as Early Phase 1. The registered enrollment target is 80 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Oregon, which has 63 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Postexercise Hypotension appearing as the primary indexed condition, and to 4 interventions - of which Aerobic Exercise is the first listed.
NCT05206227 reports 1 study location spanning 1 distinct geographic area - top geographies include Oregon.
Frequently Asked Questions
What is clinical trial NCT05206227 about?
NCT05206227 is a clinical study titled "Histamine as a Molecular Transducer of Adaptation to Exercise". This study is investigating the role of histamine in generating adaptation to exercise
What is the current status of trial NCT05206227?
This trial is currently active not recruiting. It is a Early Phase 1 study. The enrollment target is 80 participants. The study started on 2021-07-28. Estimated completion is 2027-03-31.
What conditions does trial NCT05206227 study?
This clinical trial studies the following conditions: Postexercise Hypotension.
What interventions are being tested in trial NCT05206227?
The interventions under investigation include: Aerobic Exercise (BEHAVIORAL), Antihistamine (DRUG), alpha-FMH (DRUG), Resistance and Aerobic Exercise (BEHAVIORAL).
Who is sponsoring clinical trial NCT05206227?
This trial is sponsored by University of Oregon, which has 63 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05206227 being conducted?
This trial has 1 study location across Oregon. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.